↓ Skip to main content

Dove Medical Press

Article Metrics

Targeted treatment for advanced soft tissue sarcoma: profile of pazopanib

Overview of attention for article published in OncoTargets and therapy, March 2013
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
23 Dimensions

Readers on

mendeley
22 Mendeley
Title
Targeted treatment for advanced soft tissue sarcoma: profile of pazopanib
Published in
OncoTargets and therapy, March 2013
DOI 10.2147/ott.s32200
Pubmed ID
Authors

Seth Pollack, Jones, Rajendra

Abstract

Soft tissue sarcomas comprise approximately 1% of all adult solid malignancies. While chemotherapy is the mainstay of treatment for patients with metastatic or inoperable disease, overall survival for these patients is approximately 12 months, highlighting the need for novel agents. Both laboratory and clinical data have suggested that antiangiogenic agents may have a role in the treatment of soft tissue sarcomas. Pazopanib is a multitargeted receptor tyrosine kinase inhibitor with antiangiogenic activity. The randomized, double-blind, placebo-controlled, Phase III PALETTE (pazopanib for metastatic soft-tissue sarcoma) study demonstrated improved progression-free survival in patients receiving pazopanib compared with placebo. In this review, we discuss the rationale and clinical evidence for the use of pazopanib in the treatment of metastatic and inoperable soft tissue sarcomas.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Netherlands 1 5%
Unknown 21 95%

Demographic breakdown

Readers by professional status Count As %
Researcher 5 23%
Other 3 14%
Student > Bachelor 3 14%
Student > Doctoral Student 2 9%
Student > Master 2 9%
Other 5 23%
Unknown 2 9%
Readers by discipline Count As %
Medicine and Dentistry 12 55%
Agricultural and Biological Sciences 1 5%
Business, Management and Accounting 1 5%
Economics, Econometrics and Finance 1 5%
Pharmacology, Toxicology and Pharmaceutical Science 1 5%
Other 1 5%
Unknown 5 23%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 April 2013.
All research outputs
#9,985,580
of 12,475,053 outputs
Outputs from OncoTargets and therapy
#801
of 1,548 outputs
Outputs of similar age
#100,361
of 144,193 outputs
Outputs of similar age from OncoTargets and therapy
#21
of 29 outputs
Altmetric has tracked 12,475,053 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,548 research outputs from this source. They receive a mean Attention Score of 2.4. This one is in the 32nd percentile – i.e., 32% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 144,193 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one is in the 24th percentile – i.e., 24% of its contemporaries scored the same or lower than it.